TCM
FBRX icon

TCG Crossover Management’s Forte Biosciences FBRX Stock Holding History

TCG Crossover Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Buy
+920,000
New +$21.8M 0.47% 41

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

TCG Crossover Management's FBRX Position: Q2 2026 in Review

TCG Crossover Management opened a new position in Forte Biosciences (FBRX) in Q2 2026: 920,000 shares worth $19.6M. The stake represents 0.47% of the portfolio and ranks #41 among its holdings.

79 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • TCG Crossover Management held 920,000 shares of Forte Biosciences worth $19.6M as of Q2 2026.
  • Forte Biosciences was a new TCG Crossover Management position in Q2 2026.
  • Forte Biosciences made up 0.47% of TCG Crossover Management's portfolio in Q2 2026, its #41 holding.
  • 79 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.